Canada - English - Health Canada

agila jamp canada inc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk ltd - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma ltd - vinorelbine tartrate - concentrate for soln for inf - 10 base mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

cardinal health uk 434 limited - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. it is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (nsclc). in patients with stage iv nsclc, vinorelbine is indicated as a single agent or in combination with cisplatin. in stage iii nsclc, vinorelbine is indicated in combination with cisplatin.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated in the treatment of: - non-small cell lung cancer (stage 3 or 4) - as a single agent to patients with metastatic breast cancer (stage 4), where treatment with anthracycline- and taxane containing chemotherapy has failed or is not appropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pierre fabre medicament australia pty ltd - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg - soft gelatin capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide yellow macrogol 400 medium-chain triglycerides purified water   titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

pierre fabre medicament australia pty ltd - vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg - soft gelatin capsule - 30 mg - active: vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide red macrogol 400 medium-chain triglycerides purified water   titanium dioxide